{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:40:47Z","timestamp":1792057247504,"version":"4.4.0"},"reference-count":35,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.<\/jats:p>","DOI":"10.3390\/ijms25147580","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:47:41Z","timestamp":1720774061000},"page":"7580","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1448-8601","authenticated-orcid":false,"given":"Luis Miguel","family":"Ju\u00e1rez-Salcedo","sequence":"first","affiliation":[{"name":"Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6979-2798","authenticated-orcid":false,"given":"Santosh","family":"Nimkar","sequence":"additional","affiliation":[{"name":"College of Osteopathic Medicine, Kansas City University, Kansas City, MO 64804, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Coraz\u00f3n","sequence":"additional","affiliation":[{"name":"Primary Care Medicine, Adelfas Primary Care Center, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Dalia","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology Department, Mercy Clinic Oncology and Hematology, Joplin, MI 73120, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0140-6736(19)31774-X","article-title":"Antibody-drug conjugates for cancer","volume":"394","author":"Chau","year":"2019","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): A multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1182\/blood.2020009782","article-title":"A new warhead in lymphoma therapy?","volume":"137","author":"McMillan","year":"2021","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14728214.2017.1366447","article-title":"Emerging antibody-drug conjugates for treating lymphoid malignancies","volume":"22","author":"Robak","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_18","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, D. (2019). Cancer biomarkers for targeted therapy. Biomark. Res., 7.","DOI":"10.1186\/s40364-019-0178-7"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","article-title":"Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1158\/1078-0432.CCR-19-0711","article-title":"A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma","volume":"25","author":"Kahl","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1080\/14737140.2021.1988853","article-title":"Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma","volume":"21","author":"Ahmed","year":"2021","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20406207221087511","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: A review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1016\/j.clml.2022.04.006","article-title":"Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed\/Refractory Diffuse Large B-cell Lymphoma","volume":"22","author":"Hamadani","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/bloodadvances.2023010636","article-title":"Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial","volume":"8","author":"Hamadani","year":"2024","journal-title":"Blood Adv."},{"key":"ref_29","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/hon.3166_OT29","article-title":"Lotis-5, an Ongoing Phase 3 Randomized Study of Loncastuximab Tesirine with Rituximab (lonca-R) Versus Immunochemotherapy in Patients with R\/R Dlbcl","volume":"41","author":"Kwiatek","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1182\/blood-2023-173645","article-title":"Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"142","author":"Lin","year":"2023","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/S2152-2650(23)01332-0","article-title":"ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R\/R DLBCL","volume":"23","author":"Kwiatek","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.clml.2021.11.005","article-title":"The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing after AntiCD19 CAR-T Cell Therapy","volume":"22","author":"Caimi","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Fein","year":"2023","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/bloodadvances.2020002587","article-title":"CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy","volume":"4","author":"Thapa","year":"2020","journal-title":"Blood Adv."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/14\/7580\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:12:57Z","timestamp":1760109177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/14\/7580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":35,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25147580"],"URL":"https:\/\/doi.org\/10.3390\/ijms25147580","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]}}}